By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
MYGN insiders were on both sides of the trade this year. Buys came to roughly $722,000 (three buyers), sales to $67,000 (one seller).
Phanstiel S. Louise (Director) made the biggest buy, worth around $242,000. That includes C-suite money, which tends to get the most attention.
197 investment managers listed MYGN in their latest 13F filings (Q2 2026); funds were split between buying and selling. Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
Are insiders buying or selling MYGN stock?
In the last 12 months Myriad Genetics Inc insiders made open-market purchases worth about $722,000 and sales worth about $67,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in MYGN?
The most recent open-market insider trade in MYGN was filed on 2026-06-09.
How many institutions own MYGN?
197 investment managers reported holding MYGN in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded MYGN?
No congressional trades in MYGN were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).